Tiragolumab/Atezolizumab and Chemo Offers Survival Benefit Over Chemo Alone in ESCC.
- Published in:
- OncologyLive, 2024, v. 25, n. 4, p. 57
- By:
- Publication type:
- Article
Works matching IS 23745347 AND DT 2024 AND VI 25 AND IP 4
Results: 17
1
2
Durvalumab and Bevacizumab Plus TACE Improves PFS in Embolization-Eligible, Unresectable HCC.
- Published in:
- OncologyLive, 2024, v. 25, n. 4, p. 55
- By:
- Publication type:
- Article
3
Biosimilar Pegfilgrastim-cbqv Delivery System Is Granted Approval in Febrile Neutropenia.
- Published in:
- OncologyLive, 2024, v. 25, n. 4, p. 8
- Publication type:
- Article
4
Oral HMAs May Provide Safer and More Effective Treatment Options for MDS.
- Published in:
- OncologyLive, 2024, v. 25, n. 4, p. 44
- By:
- Publication type:
- Article
5
APEX-01 Looks to Add First PSMA-Directed ADC to Treatment Paradigm in mCRPC.
- Published in:
- OncologyLive, 2024, v. 25, n. 4, p. 32
- By:
- Publication type:
- Article
6
Neoadjuvant Durvalumab Plus Chemo Boosts pCR vs Chemo Alone in Gastric/GEJ Cancers Regardless of Region.
- Published in:
- OncologyLive, 2024, v. 25, n. 4, p. 60
- By:
- Publication type:
- Article
7
Are Higher Standards for Expedited FDA Approvals Needed?
- Published in:
- OncologyLive, 2024, v. 25, n. 4, p. 41
- By:
- Publication type:
- Article
8
Data From 2023 ASH Annual Meeting Provide Positive Updates in Multiple Myeloma.
- Published in:
- OncologyLive, 2024, v. 25, n. 4, p. 17
- By:
- Publication type:
- Article
9
Capivasertib Plus Fulvestrant Approval Expands Options in Altered HR+/HER2– Breast Cancer.
- Published in:
- 2024
- By:
- Publication type:
- Interview
10
Enfortumab Vedotin Plus Pembrolizumab Receives Green Light for Metastatic Urothelial Cancer.
- Published in:
- OncologyLive, 2024, v. 25, n. 4, p. 8
- Publication type:
- Article
11
Extending the Frontiers of Checkpoint Inhibition in MCC.
- Published in:
- OncologyLive, 2024, v. 25, n. 4, p. 34
- By:
- Publication type:
- Article
12
Belzutifan gets OK for RCC.
- Published in:
- OncologyLive, 2024, v. 25, n. 4, p. 8
- Publication type:
- Article
13
PRAME Shows Promise as a Treatment Avenue in Melanoma, Other Solid Tumors.
- Published in:
- OncologyLive, 2024, v. 25, n. 4, p. 30
- By:
- Publication type:
- Article
14
Jagsi Holds a Magnifying Glass to Radiation Oncology: Uncovering Key Disparities and When to Omit Radiation in Breast Cancer.
- Published in:
- OncologyLive, 2024, v. 25, n. 4, p. 21
- By:
- Publication type:
- Article
15
Eflornithine Receives Stamp of Approval for Patients With High-Risk Neuroblastoma.
- Published in:
- OncologyLive, 2024, v. 25, n. 4, p. 8
- Publication type:
- Article
16
Phase 3 Randomized Trials: Expanding Clinically Meaningful Analysis Beyond the Stated Goals.
- Published in:
- 2024
- By:
- Publication type:
- Editorial
17
First Quarter of 2024 Sets a High Bar for Regulatory Bodies, Clinical Researchers.
- Published in:
- OncologyLive, 2024, v. 25, n. 4, p. 4
- By:
- Publication type:
- Article